Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escitalopram in Refractory Overactive Bladder
NCT00902421Phase 4Completed
- Sponsor
- Samsung Medical Center
- Start
- Jan 2007
- Primary completion
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of escitalopram in overactive bladder (OAB) (2 arms), sponsored by Samsung Medical Center. Primary endpoint: Percentage change in urgency episodes/24 hrs at 3 months. Started Jan 2007; status: completed.
02
Drugs
escitalopram
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT00902421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00902421.